FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Dilip Davda has given "May Apply" recommendation to Docmode Health Technologies IPO.
Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
---|---|---|---|---|---|
Count | 0 | 1 | 0 | 0 | 0 |
% | 0.00 | 100.00 | 0.00 | 0.00 | 0.00 |
Reviewer | Recommendation | Past Reviews |
---|---|---|
Dilip Davda | May Apply |
[Dilip Davda] The company is in the fragmented segment. Perhaps due to this, it has posted declining margins amidst competition. Though based on its FY24 annualized earnings the issue appears reasonably priced, its only for the well-informed investors for parking funds for the medium term. The tiny paid-up equity capital post listing indicates longer gestation period for migration to mainboard. Read detail review...
Docmode Health Technologies Limited peer comparison with similar listed entities. (As on March 31, 2023)
Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
---|---|---|---|---|---|---|---|
Docmode Health Technologies Limited | 8.50 | 8.50 | 16.29 | 9.30 | 56.06 | 4.85 |
Docmode Health Technologies IPO Reviews, analysis and views by popular members. Read Docmode Health Technologies Limited IPO reviews by retail investors to find recommended ipo to buy.
Post Recommendation Manage Your IPO Reviews
Review By | Apply | May Apply | Neutral | Avoid |
---|---|---|---|---|
Count | 0 | 0 | 0 | 1 |
% | 0.00 | 0.00 | 0.00 | 100.00 |
Member | Review |
---|---|
Architbhai |
Avoid Not worth the risk January 30, 2024 12:39:50 AM |
Post Recommendation Manage Recommendations
Note:
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|